MedPath

Neural and Hormonal Influences on Sex Differences in Risk for AUD

Not Applicable
Recruiting
Conditions
Alcohol Use Disorder
Interventions
Registration Number
NCT04929288
Lead Sponsor
Jessica Weafer
Brief Summary

The sex gap in alcohol consumption is closing rapidly, due to alarming increases among women. From 2002-2013, Alcohol Use Disorder (AUD) increased 84% for women, compared to 35% for men. As such, there is an urgent need to determine the factors underlying sex differences in risk for AUD. Current addiction models propose three domains that drive problematic alcohol use and serve as candidate sex-specific risk factors: executive function, negative emotionality, and incentive salience. Data suggest that poor inhibitory control, a key component of executive function, is a stronger risk factor for women than for men. Moreover, there is have preliminary evidence that female drinkers show less engagement of neural inhibitory circuitry, and that this sex difference is influenced by estradiol. However, the degree to which hormonally-moderated sex differences in executive function extend to the negative emotionality and incentive salience domains, and how these sex differences influence current and future drinking is unknown.

The goal of this study is to identify the mechanisms underlying sex-specific risk for AUD, and ultimately to help develop sex-specific prevention and treatment efforts. The overall objective of this trial is to determine the neural and hormonal factors contributing to sex-specific risk for AUD in three addiction domains: inhibitory control (executive function), negative emotionality, and alcohol cue reactivity (incentive salience).

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • consume 4/5 drinks per week
  • fluent in English
  • high school education
  • right-handed
  • regular menstrual cycles (women)
Exclusion Criteria
  • serious medical problems
  • body weight <110 or >210 lbs
  • current medical or psychiatric conditions requiring medication for which alcohol is contraindicated
  • substance use disorder other than alcohol
  • current or recent history of inpatient/intensive treatment for addictive behaviors
  • pregnant, nursing, on hormonal contraception
  • contraindications for fMRI
  • smoking > 5 cigarettes per day

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
FemalesAlcoholParticipants in this group will be adult female drinkers. Data will be segregated by menstrual cycle phase.
MalesAlcoholParticipants in this group will be adult male drinkers.
Primary Outcome Measures
NameTimeMethod
Neural inhibitory function13 minutes

The other measure of neural inhibitory function during performance of the stop signal task will be functional connectivity for the StopInh\>Go contrast.

Neural negative emotionality14 minutes

The other measure of neural negative emotionality during performance of the Emotional Pictures Task will be functional connectivity for the Negative\>Neutral contrast.

Neural alcohol cue reactivity12 minutes

The other measure of neural alcohol cue reactivity during performance of the Alcohol Cue Reactivity Task will be functional connectivity for the Alcohol\>Neutral contrast.

Intravenous alcohol self-administration (IV-ASA)60 minutes

The final measure of IV-ASA will be time to reach binge level of alcohol exposure (80mg%)

Self-reported current alcohol consumption20 minutes

The other measure of current alcohol consumption will be average peak BrAC obtained on drinking days over the past 5 days, as determined by responses on the Timeline Followback.

Prospective alcohol consumption18 months

The other measure of prospective alcohol consumption will be drinking days per month, as determined by responses on the 90-day Timeline Followback.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

The Ohio State University

🇺🇸

Columbus, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath